Last reviewed · How we verify
DE-110 ophthalmic suspension low dose
DE-110 ophthalmic suspension low dose is a Small molecule drug developed by Santen Inc.. It is currently in Phase 2 development.
At a glance
| Generic name | DE-110 ophthalmic suspension low dose |
|---|---|
| Sponsor | Santen Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy Study of DE-110 Ophthalmic Suspension for the Treatment of Dry Eye Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DE-110 ophthalmic suspension low dose CI brief — competitive landscape report
- DE-110 ophthalmic suspension low dose updates RSS · CI watch RSS
- Santen Inc. portfolio CI
Frequently asked questions about DE-110 ophthalmic suspension low dose
What is DE-110 ophthalmic suspension low dose?
DE-110 ophthalmic suspension low dose is a Small molecule drug developed by Santen Inc..
Who makes DE-110 ophthalmic suspension low dose?
DE-110 ophthalmic suspension low dose is developed by Santen Inc. (see full Santen Inc. pipeline at /company/santen-inc).
What development phase is DE-110 ophthalmic suspension low dose in?
DE-110 ophthalmic suspension low dose is in Phase 2.